Elacestrant has demonstrated modest clinical improvement in median PFS over fulvestrant and AIs in ER+/HER2− advanced breast cancer following treatment with CDK4/6i (EMERALD; ref. 29). This evidence concerns the gene ESR1 and breast cancer.